Management Team
團隊介紹
Founder & Chairman｜CEO & CMO
Hung-Kai Kevin Chen
- MD PhD
Dr. Hung-Kai Chen is the Founder, Chairman, Chief Executive Officer, and Chief Medical Officer of Elixiron Immunotherapeutics.
As a physician-scientist and biotech leader, he is recognized for his expertise in translational medicine, where he leverages patient data and biomarkers to accelerate the development of next generation precision immunotherapies.
At Elixiron, his leadership has fostered the development of several groundbreaking technologies: (1) Novel interventions that address neuroinflammatory aspects of neurodegenerative diseases—such as Alzheimer’s disease (AD)—by modulating CSF-1R signaling in brain microglia, leading to materialize of EI-1071 product currently in a Ph2 trial in AD patients. (2) Advanced target discovery programs utilizing B cell cloning and antibody library platforms, leading to the materialize of the EI-001 product which has recently completed a Ph1 study and is in preparation of a Ph2 in vitiligo patients. (3) The T-action platform, which significantly boosts T cell activity within tumors, leading to the EI-011 product that has been out-licensed to Pilatus Biosciences for oncology applications.
In addition to his leadership in R&D teams, he has also led the business team to raise over $70M in capital to advance two first-in-class precision immunotherapies into PoC clinical trials, EI-1071 and EI-001.
Before founding Elixiron, Dr. Chen held senior leadership roles across the pharmaceutical and biotech industries. He served as SVP and CMO at Eusol Biotech, leading clinical programs in neurological disorders; as Director of Translational Medicine at the DCB, Taiwan, where he helped build a robust immune-oncology pipeline and advance preclinical candidates including anti-TIM3 and CSF-1R inhibitors; and at GSK’s Neuroimmunology Discovery Performance Unit in Shanghai, where he led discovery teams from early target validation to lead optimization, and contributed to global biomarker and translational strategies for Ph2 clinical trials.
Earlier in his career, Dr. Chen was Assistant Investigator at the Gladstone Institutes’ Translational Research Center in San Francisco, where he collaborated with Merck on a multi-million-dollar program to develop small molecule drugs for AD.
His contributions have been recognized with prestigious international awards, including the 2022 Alzheimer’s Association Part the Cloud Award ($0.8M), the 2020 Part the Cloud–Gates Partnership Grant ($1M), and the 2020 National Innovation Award (Gold Medal). Dr. Chen has also published in leading journals such as Cell, Nature Medicine, and Cancer Discovery.
BACK
返回
As a physician-scientist and biotech leader, he is recognized for his expertise in translational medicine, where he leverages patient data and biomarkers to accelerate the development of next generation precision immunotherapies.
At Elixiron, his leadership has fostered the development of several groundbreaking technologies: (1) Novel interventions that address neuroinflammatory aspects of neurodegenerative diseases—such as Alzheimer’s disease (AD)—by modulating CSF-1R signaling in brain microglia, leading to materialize of EI-1071 product currently in a Ph2 trial in AD patients. (2) Advanced target discovery programs utilizing B cell cloning and antibody library platforms, leading to the materialize of the EI-001 product which has recently completed a Ph1 study and is in preparation of a Ph2 in vitiligo patients. (3) The T-action platform, which significantly boosts T cell activity within tumors, leading to the EI-011 product that has been out-licensed to Pilatus Biosciences for oncology applications.
In addition to his leadership in R&D teams, he has also led the business team to raise over $70M in capital to advance two first-in-class precision immunotherapies into PoC clinical trials, EI-1071 and EI-001.
Before founding Elixiron, Dr. Chen held senior leadership roles across the pharmaceutical and biotech industries. He served as SVP and CMO at Eusol Biotech, leading clinical programs in neurological disorders; as Director of Translational Medicine at the DCB, Taiwan, where he helped build a robust immune-oncology pipeline and advance preclinical candidates including anti-TIM3 and CSF-1R inhibitors; and at GSK’s Neuroimmunology Discovery Performance Unit in Shanghai, where he led discovery teams from early target validation to lead optimization, and contributed to global biomarker and translational strategies for Ph2 clinical trials.
Earlier in his career, Dr. Chen was Assistant Investigator at the Gladstone Institutes’ Translational Research Center in San Francisco, where he collaborated with Merck on a multi-million-dollar program to develop small molecule drugs for AD.
His contributions have been recognized with prestigious international awards, including the 2022 Alzheimer’s Association Part the Cloud Award ($0.8M), the 2020 Part the Cloud–Gates Partnership Grant ($1M), and the 2020 National Innovation Award (Gold Medal). Dr. Chen has also published in leading journals such as Cell, Nature Medicine, and Cancer Discovery.
